论文部分内容阅读
1 材料与方法 1.1 病例选择 80例均为1997年12月～1998年12月住院的慢性乙型肝炎病人。均符合1995年北京全国肝炎会议修订的诊断标准。治疗组40例,男33例,女7例,年龄7～45岁,平均31岁。对照组40例,女10例,年龄10～50岁,平均32岁。两组的性别、年龄分布相似(P>0.05)。两组HBsAg、HBeAg、抗-HBc及HBV DNA均为阳性。 1.2 治疗方法 治疗组及对照组在保肝药物及对症支持治疗方面相同。治疗组加服拉米夫定(系英国葛兰素威康公司产品,商品名3TC)进行抗病毒治疗,12岁以下每日服用75mg,12岁以上每日服150mg,疗程为6个月。对照组不用任何抗病毒
1 Materials and Methods 1.1 Case Selection 80 cases were hospitalized in patients with chronic hepatitis B from December 1997 to December 1998. Are in line with the 1995 Beijing National Hepatitis Conference revised diagnostic criteria. Treatment group of 40 patients, 33 males and 7 females, aged 7 to 45 years, mean 31 years. Control group 40 cases, 10 females, aged 10 to 50 years, mean 32 years. The gender and age distribution of the two groups were similar (P> 0.05). Two groups of HBsAg, HBeAg, anti-HBc and HBV DNA were positive. 1.2 Treatment The treatment group and the control group in liver protection drugs and symptomatic treatment support the same. The treatment group plus lamivudine (Department of Glaxo Wellcome UK products, trade name 3TC) for antiviral therapy, daily doses of 75mg under the age of 12, over the age of 12 150mg daily service for 6 months. Control group without any antiviral